Aktieanalys

IRLAB: Successfully completed first part of phase I IRL757 study - Redeye

{newsItem.title}

Redeye Publicerad: 04 Oct 07:30

IRLAB Therapeutics

Redeye gives a comment on today’s news that IRLAB has successfully completed the first part of the phase I trial with IRL757, targeting apathy.

Länk till analysen i sin helhet: https://www.redeye.se/research/1041850/irlab-successfully-completed-first-part-of-phase-i-irl757-study?utm_source=finwire&utm_medium=RSS

Nyheter om IRLAB Therapeutics

Läses av andra just nu

Om aktien IRLAB Therapeutics

Senaste nytt